Published in Hepatitis Weekly, January 28th, 2002
The objective of the study, called AEGIS (Antifibrotic Efficacy Gamma Interferon Study), is to evaluate the safety and antifibrotic activity of Actimmune in HCV patients who have failed standard antiviral therapy.
More than 4 million people are affected with HCV in the United States, and current antiviral therapy for HCV infection is effective in only approximately 50% of patients. Because treatment is often not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.